Abstract
P-203 SLCG 9901: phase II trial with cisplatin (cis), gemcitabine (gem) and docetaxel (doc) as neoadjuvant treatment in stage IIIA N2 and T4N0-1 non-small cell lung cancer (NSCLC) patients
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
